Melazyme Raises $2M Seed Round Led by SeaX Ventures
Utah-based precision fermentation startup Melazyme announced the closing of a $2 million seed round, led by Bangkok deep‑tech fund SeaX Ventures with participation from Stellaris Venture Partners and Plug and Play Ventures. The funding will support platform development, production scale‑up, and early commercial deployment of its melanin and brazzein molecules for cosmetics, industrial and environmental applications.
Apogee Therapeutics Secures $1.3B Royalty Financing From Blackstone Life Sciences
Apogee Therapeutics announced a $1.3 billion royalty financing agreement with Blackstone Life Sciences, comprising $800 million in synthetic royalties and a $500 million senior‑debt option. The deal grants Blackstone up to a 6.25% royalty on worldwide sales of Apogee’s atopic dermatitis candidate zumilokibart...
PacificoBiolabs Raises $7.6M Series A to Turn Brewery Infrastructure Into Protein Production
PacificoBiolabs, a mycelium‑fermentation protein startup, announced a €7 million ($7.6 million) Series A round backed by Stray Dog Capital, TGFS, Sprout & About Ventures, Simon Capital, FoodLabs and a regional brewery partner. The funding will be used to scale production in Saxony, expand...
IFAST Diagnostics Secures $6.35M Funding to Accelerate Rapid Infection Testing
UK biotech iFAST Diagnostics closed a £5 million ($6.35M) funding round led by Meridian Health Ventures, with participation from QantX, RAW Ventures, OKG Capital, Cambridge Capital Group and a £2.1 million loan from Innovate UK. The capital will fund UK rollout, EU approval...
Protuoso Biosciences Raises $9.5M Seed Financing
Protuoso Biosciences, a California biotech developing multifunctional biologics, closed a $9.5 million seed round. The financing was led by Taya Venture and Darwin Ventures, with participation from NSG Ventures, SEEDS and others. The funds will be used to advance its MUXBODIES...
Hansa Biopharma Sells European Commercial Rights for Idefirix to SERB Pharmaceuticals for $121M
Swedish biotech Hansa Biopharma AB entered a commercial rights agreement with SERB Pharmaceuticals, transferring Idefirix rights for Europe, the Middle East and North Africa. SERB will pay €110 million (~$121 million) upfront and up to €5 million (~$5.5 million) upon full approval, providing Hansa...
Alcolase Raises $1.65M Seed Round
Danish biotech startup Alcolase announced a €1.5 million ($1.65 million) seed round to develop its enzyme‑based supplement for ALDH2 deficiency. The round was backed by Ada Ventures, Delphinus Venture Capital, Antler, Manigoff Invest and several business angels. The funding will...
StrainX Bioworks Raises $13M in Funding Round Led by Prime Venture Partners and Leo Capital
Synthetic biology startup StrainX Bioworks announced a $13 million funding round co‑led by Prime Venture Partners and Leo Capital, with participation from Good Startup, Sparrow Capital, Sun Icon Ventures, Dhoka Ventures and WTF (India) Delhi Angels. The capital will be used...
Gilead Sciences Completes Tubulis Acquisition for up to $5bn
Gilead Sciences has completed its acquisition of German biotech Tubulis for up to $5 bn, paying $3.15 bn upfront with up to $1.85 bn in milestones. The deal gives Gilead access to Tubulis’ ADC platform and pipeline, including TUB‑040 and TUB‑030, strengthening its...
Retro Biosciences Raises New Funding, Valued at $1.8B
Longevity startup Retro Biosciences announced a new fundraising round that values the company at $1.8 billion. The round was backed by OpenAI CEO Sam Altman. Retro is developing gene and cell therapies to extend healthy human lifespan and is currently running...
B-COS Raises $1.1M Pre-Seed Round to Scale Precision-Fermented Crop-Protection Products
Ghent University spin-off B-COS announced the closing of a €1M ($1.1M) pre-seed funding round backed by Agri Investment Fund, Boerenbond's venture-capital fund and VP Capital. The capital will be used to scale its precision-fermented crop-protection platform, advance regulatory approvals and...
Macmillan Cancer Support Launches Macmillan Ventures VC Fund to Back Cancer Care Innovations
Macmillan Cancer Support has launched Macmillan Ventures, a new venture capital fund backed by donations from philanthropists and organisations to invest in cancer treatment innovations. The fund follows the charity’s prior investments of over $4.4 million since 2023, including participation in...
Efferon Secures €2.5M ($2.75M) Seed Round to Grow Blood‑purification Platform
Biotech firm Efferon closed a €2.5 million seed round led by private investors from the DACH region. The funding will support the European commercial rollout of its hemoadsorption device Efferon LPS and the construction of a new EU production facility, expanding...
Conexeu Sciences Inc. (CNXU) Launches IPO on Nasdaq, Raising Capital for Regenerative Medicine
Reno‑based Conexeu Sciences Inc. (Nasdaq: CNXU) completed its initial public offering and began trading on Nasdaq on May 21, 2026, issuing 25.3 million shares. The biotech firm, focused on regenerative tissue scaffolds such as its B.R.E.A.S.T.™ product, will use the proceeds to advance...
Degron Secures $40M Series A Funding to Advance Molecular Glue Degraders
Degron, a biotech company focused on molecular glue degraders, announced the closing of a $40 million Series A financing round. The funding will be used to accelerate development of its molecular glue degrader platform.